Aurobindo sued by Pfizer over skin antibiotic

Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pfizer sues India generic drugmaker over cancer drug

14 January 2021 Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

Americas

Pfizer to settle Xeljanz suit with Teva

9 September 2021 Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.

Americas

Biofrontera settles patent dispute with Dusa over skin treatment

30 November 2021 A US subsidiary of German skin treatment company Biofrontera has resolved its dispute with Dusa Pharmaceuticals, on the eve of a trial over patents covering a light therapy used to treat skin conditions, called BLU-U.

More on this story

Big Pharma

Pfizer sues India generic drugmaker over cancer drug

14 January 2021 Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

Americas

Pfizer to settle Xeljanz suit with Teva

9 September 2021 Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.

Americas

Biofrontera settles patent dispute with Dusa over skin treatment

More on this story

Big Pharma

Pfizer sues India generic drugmaker over cancer drug

14 January 2021 Pharmaceutical company Pfizer has accused generic drug maker Aurobindo of infringement, as it attempts to block the roll-out of copies of its blockbuster arthritis drug, Xeljanz.

Americas

Pfizer to settle Xeljanz suit with Teva

9 September 2021 Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.

Americas

Biofrontera settles patent dispute with Dusa over skin treatment